MedTrace Logo

Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy

NCT04690608 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-03-05

No results posted yet for this study

Summary

Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).

Conditions

  • Retinal Edema

Interventions

DRUG

Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1

suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Amin E Nawar, Lecturer · Tanta University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2024-12-01
Completion
2025-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04690608 on ClinicalTrials.gov